Shukra Pharmaceuticals
BSE 524632
5 stories, newest first.
- Board meeting rescheduled to 4 November 2026 to consider Q2 and half-year results
- Board meeting on 3 November 2026 to consider Q2 and half-year unaudited results
- MCA approves change of name; fresh Certificate of Incorporation issued
- Board approves allotment of 17,35,000 equity shares on conversion of warrants
- Clarification on recent price movement: no undisclosed price-sensitive information
Nothing here is a view, opinion or recommendation of ScoutQuest, its parent, directors or employees. ScoutQuest is a technology company: this page was assembled automatically from public sources using artificial intelligence, and may contain errors or omissions. Confirm everything against the original source before you act on it. Any use of this page is at your own risk, and neither ScoutQuest nor its parent, directors or employees accepts liability for it.